DoD’s $41M Wafermine Contract Is Separate From iX Biopharma’s Pending Manufacturing JV

The U.S. Department of Defense (DoD) awarded iX Biopharma a US$41 million contract in February 2026 to develop Wafermine, a ketamine-based sublingual wafer pain treatment intended for military use, including battlefield applications. The work includes clinical trials and activities related to seeking emergency-use authorization. The award is a distinct development effort, not the same arrangement as iX Biopharma’s proposed U.S. manufacturing joint venture with Orion Specialty Labs. That distinction matters to government customers, prospective subcontractors and suppliers assessing which workstreams are funded, who is responsible for delivery, and what dependencies could affect performance.

The proposed Orion venture has attracted attention because the companies have not signed a joint venture agreement and Orion has not yet obtained a Nevada state licence. In a response to questions from the Singapore Exchange (SGX), iX Biopharma said negotiations were at an advanced stage but that final terms, due diligence and tax assessments remained under discussion. The company stated that the licensing status does not affect the DoD contract or its U.S. expansion plans. It also clarified that its earlier reference to Orion’s “regulatory licences” meant, in part, the facility’s registration with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility—not a Nevada operating licence.

For contractors and suppliers, the immediate procurement takeaway is to separate the DoD-funded product-development scope from the prospective commercial manufacturing arrangement. The company says Orion’s pending state licence does not change the award; the source does not describe the contract as contingent on the joint venture being finalized. Nevertheless, the manufacturing partnership could be relevant to later production and commercialization plans, so firms evaluating a role in the broader supply chain should verify the applicable work package, contracting relationship, facility status and required approvals rather than treating the two arrangements as interchangeable.

Execution and funding conditions warrant attention. iX Biopharma says reimbursement follows costs already incurred, which can require the contractor to finance work before receiving payment. That structure may influence working-capital planning, the pace of spending and the timing of payments to subcontractors. The company has also shifted its expected emergency-use submission from Q4 2026 to “within the next 12 months.” Clinical-trial progress and regulatory milestones therefore remain important schedule variables. The source also reports analyst concerns about trial delays, rejection of an emergency-use application, weaker licence terms and possible additional funding needs; these are identified risks, not confirmed outcomes.

• Award value and timing: The DoD awarded iX Biopharma a US$41 million Wafermine development contract in February 2026.
• Purpose and scope: Wafermine is a ketamine-based sublingual wafer treatment intended for military use; the work includes clinical trials and emergency-use authorization activities.
• Separate arrangement: iX Biopharma says the DoD contract is separate from its proposed manufacturing joint venture with Orion Specialty Labs.
• Partner status: The joint venture agreement remains unsigned, and Orion has not yet obtained a Nevada state licence; negotiations, due diligence, final terms and tax assessments were still in progress as described in the source.
• Regulatory clarification: iX said its earlier reference to Orion’s regulatory licences referred to its FDA 503B outsourcing facility registration, among other context, rather than a Nevada state operating licence.
• Payment exposure: Reimbursement follows costs already incurred, making the contractor’s ability to carry expenses before payment relevant to delivery and subcontractor planning.
• Schedule revision: The expected emergency-use submission moved from Q4 2026 to within the next 12 months; clinical-trial and regulatory milestones remain material.
• Risks flagged in reporting: Analysts cited possible trial delays, rejection of an emergency-use bid, weaker licence terms and additional funding needs. These are potential risks, not reported contract outcomes.
• Action for suppliers: Confirm whether an opportunity falls under the DoD development contract or the proposed Orion manufacturing venture, and assess the relevant payment, schedule and facility-approval dependencies.